Zevra Therapeutics (ZVRA) Long-Term Investments (2016 - 2026)

Zevra Therapeutics (ZVRA) has 7 years of Long-Term Investments data on file, last reported at $36.1 million in Q1 2026.

• Quarterly Long-Term Investments rose 493.42% year-over-year to $36.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.1 million (up 493.42% YoY) and the FY2025 annual result came in at $47.9 million, up 696.66% from the prior year.
• Long-Term Investments fell to $36.1 million in Q1 2026, from $47.9 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $47.9 million in Q4 2025 to a low of $6.0 million in Q4 2024.
• A 4-year average of $20.6 million and a median of $17.6 million in 2022 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2022 — Long-Term Investments jumped 3981.63% — and 2025, when it jumped 405.57%.
• Tracing ZVRA's Long-Term Investments over 4 years: stood at $20.0 million in 2022, then sank by 69.95% to $6.0 million in 2024, then jumped by 696.66% to $47.9 million in 2025, then fell by 24.51% to $36.1 million in 2026.
• The last three Long-Term Investments figures came in at $36.1 million (Q1 2026), $47.9 million (Q4 2025), and $30.9 million (Q3 2025), per Business Quant data.